Obagi Medical Products Introduces Hydrate

Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin-health systems, announces the launch of Obagi Hydrate. This new moisturizer is available as a standalone product, and also as part of the clinically proven Obagi Nu-Derm ® System, a line specially formulated to prevent the signs of aging at the cellular level to reveal transformed, healthy skin.

“Our customers and their patients have been asking for a moisturizer for years; we’re happy to be bringing to market a product that is clinically proven to do what it says it will do,” Al Hummel, Chief Executive Officer at Obagi, said. “Obagi Hydrate offers both instant and long-lasting hydration and is a great adjunct to any of our other Obagi Systems.”

While many moisturizers work by occlusion, a process that consists of forming a film on the skin to prevent dehydration, Obagi Hydrate is a unique formula that features innovative technology called Hydromanil. This primary ingredient in the technology captures water and assimilates it into the skin both immediately and lastingly due to an advanced multi-capillary process, creating a two-in-one response: reduced water loss on skin’s surface and the continuous release of active moisturizing and water-retaining compounds. This results in long-lasting hydration, supported by hyper-moisturizing ingredients such as shea butter, mango butter, avocado and glycerin, which further help combat dryness.

Clinical trials have also shown a 51-percent improvement in moisture loss after eight hours and a 92-percent improvement in the skin’s moisture retention within two hours 1. After extensive dermatological testing, Hydrate was shown to have no specific negative clinical reactions, proving it to be non-irritating, non-sensitizing, hypoallergenic and noncomedogenic.

OBAGI Nu-Derm Hydrate (MSRP $45, 1.7 oz) is available for purchase in dermatology, plastic surgery and other aesthetic physicians’ practices.

About Obagi Medical Products, Inc.

Obagi Medical Products is a specialty pharmaceutical company that develops, markets and sells, and is a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. Using its Penetrating Therapeutics™ technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. Obagi Medical’s portfolio, which includes cosmetic, over-the-counter and prescription products, including 4% hydroquinone, is sold and promoted only through physician offices and requires education by a physician on proper use. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm®, Obagi-C® Rx (a prescription-strength vitamin C and hydroquinone system), Obagi® Professional-C (a line of highly stable vitamin C serums), Obagi Condition &Enhance® for use with cosmetic procedures to enhance patient outcomes and satisfaction, Obagi ELASTIderm® Eye Products and Obagi CLENZIderm® M.D. acne therapeutic systems, a formulation of Obagi CLENZIderm M.D. Systems for normal to dry skin, and Obagi ELASTIderm Décolletage System, Obagi Rosaclear® System, Obagi ELASTILash® Eyelash Solution, Obagi Blue Peel RADIANCE ®, and Nu-Derm® Sun Shield SPF 50. Visit www.obagi.com for information.

Penetrating Therapeutics and Obagi Hydrate are trademarks, and Obagi, the Obagi logo, Blue Peel RADIANCE, Condition & Enhance, ELASTIderm, ELASTILash, Nu-Derm, Obagi-C, Obagi CLENZIderm and Rosaclear are registered trademarks, of Obagi Medical Products, Inc. and/or its affiliates in the United States and certain other countries.

1 TEWL/Moisturization Evaluation, OMP, Inc. Data on file.

Copyright Business Wire 2010

If you liked this article you might like

The Five Dumbest Things on Wall Street: April 12

Merz Withdrawal Frees Obagi-Valeant Merger

Valeant Buys Obagi Medical for $360 Million

Obagi Medical Products Inc. Stock Downgraded (OMPI)

5 Hated Stocks Set to Soar on Earnings